Dear investors and analysts,

We’ve noticed an increasing number of our engagements are incorporating environment, social, and governance topics – with some investors looking for ESG-specific meetings and others looking for a high-level overview of our approach and a summary of new updates.

In an effort to share the latest and greatest with you, we pulled together this quarterly ESG note to highlight our priorities, recent activity, hot topics and news flow.

As always, we’d love to hear from you so please reach out to our team with your comments and questions.

Thank you,

GSK Investor Relations
IRTeam@gsk.com

Six areas of focus

We are guided by our purpose to unite science, technology, and talent to get ahead of disease together. Integral to this is running a responsible business, one which builds trust and reduces risk to deliver sustainable health impact at scale, shareholder returns, and to support our people to thrive. To do so, we have prioritised our resources to focus on six material areas:

* Access
* Global health and health security
* Diversity, equity and inclusion
* Environment
* Product governance
* Ethical standards
Progress against our areas of focus

Click below to access the news articles

**Access:**
- GSK tops Access to Medicine Index (ATMI) for eighth consecutive time
- ViV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine
- ViV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
- ViV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV

**Environment:**
- GSK launches Sustainable Procurement Programme for suppliers

**Product governance:**
- Statement: Zantac (ranitidine) litigation

**Global health and health security:**
- EAGLE-2 and EAGLE-3 phase III trials for gepotidacin stopped early for efficacy following pre-planned interim analysis by Independent Data Monitoring Committee
- GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D
- GSK and Microsoft, in collaboration with the Centre for Health and Disease Studies, launch disease surveillance project in Nepal
- WHO grants prequalification to GSK’s Mosquirix — the first and only approved malaria vaccine
- GSK signs agreement to support pandemic preparedness in Europe
- GSK gathers global experts to discuss role of vaccines in protecting people and the planet
- GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
- GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis

ESG IR Event Spotlight:
In April, GSK IR provided an updated on our Environmental strategy and goals, connection to long-term value creation, and integration into operations as well as an update on our targets and progress. Slides, transcript and event replay are available on our website.

“Delivering our ambitious sustainability goals is at the heart of GSK’s purpose, strategy and culture, and a key driver in our goal to deliver health impact and long-term growth.”

Clare Lund, VP Sustainability, GSK
Recent questions from investors:

1. What is the role of GSK in novel antibiotics?

Our AMR-relevant research includes programs targeting pathogens deemed “critical” and “urgent” by the WHO and the US CDC. The most recent AMR Benchmark highlighted the diversity of our R&D, recognising us as having 31 relevant projects, balanced across antibacterial medicines and vaccines. This includes gepotidacin, a potential first new novel oral antibiotic treatment for uUTIs in over 20 years.

We also entered into an exclusive license agreement with Spero Therapeutics to add a late-stage antibiotic, tebipenem for the potential treatment of cUTIs, to our pipeline. Vaccines are also an important tool against AMR as they can reduce the need for antibiotic treatment, limiting opportunities for resistance. We are excited about the potential of new technologies and recently brought in a vaccine technology that could help target bacterial pathogens.

2. Does remuneration for senior leaders tie to ESG targets?

Remuneration Committee, with the full support of the Corporate Responsibility Committee, has initially introduced a 10% ESG measure into both our short and long-term incentive plans, to reward delivery of external ambitions for our Trust priority. They are: Human Capital Management in the form of Inclusion and Diversity (which forms 10% of the annual bonus opportunity) and our Climate Net Zero and Nature Net Positive ambitions by 2030 (which forms 10% of our long-term incentive plan opportunity).

In lower income countries we use innovative pricing structures to extend product reach, including tiered pricing for vaccine tenders based on World Bank income classification. We also work with partners with the right capability, geographic reach, and local knowledge.

We recognise we can, and must, do more. We are renewing and extending our commitment to access for patients in lower income countries by applying everything we have learned to date. We are systematically evaluating our pipeline and portfolio with global health partners. This will identify products with the greatest impact and develop access plans that benefit people most in need in these countries.

More information on our pricing and access position can be found here.

3. How do you provide access to your products in lower and middle income countries?

In lower income countries we use innovative pricing structures to extend product reach, including tiered pricing for vaccine tenders based on World Bank income classification. We also work with partners with the right capability, geographic reach, and local knowledge.

We recognise we can, and must, do more. We are renewing and extending our commitment to access for patients in lower income countries by applying everything we have learned to date. We are systematically evaluating our pipeline and portfolio with global health partners. This will identify products with the greatest impact and develop access plans that benefit people most in need in these countries.

More information on our pricing and access position can be found here.
Committed to ESG investor engagement

Rating agencies updates

#1 in ATMI¹

AA rating from MSCI

Rating from CDP

Climate: A-
Water security: B
Forest timber: B
Forest Palm Oil: A-
(improved one level from 2021)

Industry leader on the AMR² Benchmark

2nd in the Pharmaceutical industry in S&P Corporate Sustainability Assessment (results as of 20 January 2023)

Stay tuned
Next quarter we look forward to providing performance updates on our ESG metrics following the publishing of our 2023 ESG report

¹. Access to Medicines Index
². Antimicrobial Resistance